Novoste Announces New Vice President, Scientific Affairs and Strategic Development and Vice President, Global Clinical Affairs.Health/Medical Writers NORCROSS, Ga.--(BW HealthWire)--April 1, 2002 Novoste Corporation (Nasdaq: NOVT) today announced that Richard J. diMonda has assumed responsibilities as Vice President, Scientific Affairs and Strategic Development and Pia Mikkelsen Lynch, M.D. has joined its senior management team as Vice President, Global Clinical Affairs. Both positions will report directly to Thomas D Thomas D. (born Thomas Dürr, December 30 1968 in Ditzingen close to Stuttgart, Germany) is a rapper in the German hip hop group Die Fantastischen Vier. He frequently works on solo projects. Life After finishing Realschule he took on an apprenticeship as a barber. . Weldon, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . Mr. diMonda joined Novoste Corporation in September 1997 as Senior Director of Strategic Marketing and has served as a member of the Novoste Corporation senior management team since April 2000, most recently as Vice President, Clinical and Strategic Development. From 1987 to 1997, Mr. diMonda served as Director of Corporate Development with Dornier Medical Systems, Inc. From 1976 to 1987, Mr. diMonda was employed by the American Hospital Association American Hospital Association (AHA), n.pr a nonprofit national organization of individuals, institutions, and organizations engaged in direct patient care. The association works to promote the improvement of health care services. as Director, Division of Clinical Services and Technology. Mr. diMonda received a M.B.A. degree from Keller Graduate School of Management, a M.S. degree in Biomedical Engineering Biomedical engineering An interdisciplinary field in which the principles, laws, and techniques of engineering, physics, chemistry, and other physical sciences are applied to facilitate progress in medicine, biology, and other life sciences. from Drexel University Drexel University, at Philadelphia, Pa.; coeducational; founded 1891 by Anthony J. Drexel, opened 1892, chartered 1894 as Drexel Institute of Art, Science, and Industry. It was renamed Drexel Institute of Technology in 1936 and gained university status in 1970. , and a B.S. degree in Electrical Engineering electrical engineering: see engineering. electrical engineering Branch of engineering concerned with the practical applications of electricity in all its forms, including those of electronics. from Villanova University. Dr. Lynch joins Novoste Corporation from Elan Pharmaceutical Research Corporation, where she served as Director, Clinical Research since 1997. In this role, she was responsible for developing business and clinical strategies for various projects in multi-therapeutic areas, as well as managing all worldwide clinical development programs for Phase I through IV studies. From 1996 to 1997, Dr. Lynch served as Medical Project Manager, at Worldwide Clinical Trials, Inc., where she directed global clinical research organization services for Phase I through III clinical trials. From 1995 to 1996, she was employed as a Medical Consultant with Integrated Micro Technologies, Inc. and from 1991 through 1994, Dr. Lynch served as a post-graduate research fellow in the Department of Hematology and Oncology at the University of Aarhus History It was founded in 1928 as Universitetsundervisningen i Jylland ("University Teaching in Jutland") in classrooms rented from the Technical College and a teaching corps consisting of one professor of philosophy and four Readers of Danish, English, German and , Denmark. Dr. Lynch holds a Doctor of Medicine (M.D.) degree from the University of Aarhus, Denmark. Thomas D. Weldon, Chairman and CEO, commented, "Mr. diMonda's new assignment will allow us to concentrate on our company's most critical need, which is business development activities that will yield both short-term revenues as well as longer-term new opportunities. His focused leadership will allow us to more quickly broaden our technology and product platform. He will continue to work closely with Dr. Raoul Bonan, our Medical Director, and will be responsible for developing clinical strategies for animal trials and human feasibility trials and for mining the data from our current clinical research." Mr. Weldon added, "Dr. Lynch's experience in both FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. drug and device research trials will prove invaluable as we continue to explore new opportunities outside of the traditional "catheter" area. Dr. Lynch will be responsible for the design and execution of the definitive clinical trials and management of the Medical Services department. We are fortunate to have attracted someone of her caliber for this strategically important role." About Novoste Corporation: Novoste Corporation, based in Atlanta, GA, develops advanced medical treatments for coronary and vascular diseases vascular diseases, n.pl diseases of the peripheral circulatory system. and is the worldwide leader in vascular brachytherapy. The company's Beta-Cath(TM) System is commercially available in the United States, as well as in the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community and several other countries. Novoste Corporation shares are traded on the NASDAQ National Stock Market under the symbol NOVT. For general company information, please call (770) 717-0904 or visit the company's web site at www.novoste.com. Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes regarding future occurrences are forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Actual results may differ materially from those projected in these forward-looking statements based upon risks and uncertainties, such as product availability, continued market acceptance of the Beta-Cath(TM) System, continued demonstration of safety, efficacy, and device performance in post-market surveillance studies, competition and technological changes and other risks detailed in documents filed by Novoste with the SEC including its Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2001. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion